What's Happening?
Crown Bioscience, a global contract research organization and a JSR Life Sciences company, has announced that its San Diego laboratory has achieved accreditation from the College of American Pathologists
(CAP). This achievement builds on the laboratory's previous Clinical Laboratory Improvement Amendments (CLIA) certification, which was obtained in July 2025. The CAP accreditation is a significant milestone that enhances the laboratory's ability to deliver clinical-grade biomarker testing, supporting regulated drug development programs. The accreditation is recognized as a benchmark for laboratory quality, ensuring operational excellence, technical competence, and quality oversight. This development positions Crown Bioscience to better support clinical trials with reliable data, aiding in the advancement of innovative therapies.
Why It's Important?
The CAP accreditation of Crown Bioscience's San Diego laboratory is crucial for the biotechnology and pharmaceutical industries, particularly in the fields of oncology and precision medicine. By meeting rigorous quality standards, the laboratory can provide high-quality biomarker testing, which is essential for the development of new therapies. This accreditation not only enhances the laboratory's credibility but also strengthens its role as a trusted partner for companies seeking to advance their drug discovery and development efforts. The ability to deliver reliable data is critical as studies transition from translational research to clinical applications, ensuring that new therapies can be developed more efficiently and effectively.
What's Next?
With the CAP and CLIA accreditations in place, Crown Bioscience's San Diego laboratory is poised to integrate biomarker testing more closely across preclinical and clinical workflows. This integration will support continuity of data and alignment with regulatory requirements throughout the drug development process. The laboratory's enhanced capabilities are expected to attract more partnerships with biotechnology and pharmaceutical companies, further expanding its role in advancing oncology and precision medicine programs. As the laboratory continues to grow its global network of accredited facilities, it will likely play a pivotal role in the development of innovative therapies.
